E-LIB Suche - Ergebnisse für: SHAH, A.N.

1

MICROFLUIDIC SEPARATION TECHNOLOGY IMPROVES PURITY AND YIEL..:

Song, H.W. ; Underwood, S. ; Traynor, R....
Cytotherapy. 26 (2024) 6 - p. S26 , 2024

Link: https://doi.org/10.1016/..

2

SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS DISTINCT CHARACT..:

Shao, L. ; Shi, R. ; Cai, Y....
Cytotherapy. 26 (2024) 6 - p. S12-S13 , 2024

Link: https://doi.org/10.1016/..

3

Brentuximab vedotin (BV) + AVD for newly diagnosed classic ..:

Bowers, J. T. ; Anna, J. ; Bair, S. M....
Hematological Oncology. 41 (2023) S2 - p. 359-360 , 2023

Link: https://doi.org/10.1002/..

4

Process Development and Manufacturing: CAR-T CELLS MANUFACT..:

Song, H.W. ; Benzaoui, M. ; Underwood, S....
Cytotherapy. 25 (2023) 6 - p. S9 , 2023

Link: https://doi.org/10.1016/..

5

Long‐term safety with ≥12 months of pirtobrutinib in relaps..:

Wang, Y. ; Coombs, C. C. ; Shah, N. N....
Hematological Oncology. 41 (2023) S2 - p. 480-481 , 2023

Link: https://doi.org/10.1002/..

6

Health‐related quality of life in patients with relapsed or..:

Maloney, D. G. ; Siddiqi, T. ; Fakhri, B....
Hematological Oncology. 41 (2023) S2 - p. 538-541 , 2023

Link: https://doi.org/10.1002/..

7

BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR..:

Ulrickson, M. ; Miklos, D. B. ; Maziarz, R. T...
Hematological Oncology. 41 (2023) S2 - p. 147-147 , 2023

Link: https://doi.org/10.1002/..

8

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:

Siddiqi, T. ; Maloney, D. G. ; Kenderian, S. S....
Hematological Oncology. 41 (2023) S2 - p. 60-62 , 2023

Link: https://doi.org/10.1002/..

9

HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 ..:

Cho, S. ; Nair, R. ; Jacobs, R....
Hematological Oncology. 41 (2023) S2 - p. 127-129 , 2023

Link: https://doi.org/10.1002/..

10

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALE..:

Patel, K. ; Brown, J. R. ; Desikan, S. P....
Hematological Oncology. 41 (2023) S2 - p. 185-187 , 2023

Link: https://doi.org/10.1002/..

11

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:

Cheah, C. Y. ; Shah, N. N. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 153-156 , 2023

Link: https://doi.org/10.1002/..

12

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Mato, A. R. ; Pagel, J. M. ; Coombs, C. C....
HemaSphere. 6 (2022) - p. 48-49 , 2022

Link: https://doi.org/10.1097/..

13

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Roeker, L. E. ; Mato, A. R. ; Brown, J. R....
HemaSphere. 6 (2022) - p. 538-539 , 2022

Link: https://doi.org/10.1097/..

14

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUD..:

Eyre, T. A. ; Shah, N. N. ; Le Gouill, S....
HemaSphere. 6 (2022) - p. 990-991 , 2022

Link: https://doi.org/10.1097/..

15

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:

Eyre, T. A. ; Wang, M. L. ; Shah, N. N....
HemaSphere. 6 (2022) - p. 991-992 , 2022

Link: https://doi.org/10.1097/..